78495-63-3 Usage
Description
2-Fluoro-6-methoxyphenylboronic acid is a boronic acid derivative characterized by the presence of a fluorine atom at the 2nd position and a methoxy group at the 6th position on a phenyl ring. It is known for its pharmacological activity and is utilized as an intermediate in the synthesis of various compounds, including those with potential applications in the medical and chemical industries.
Uses
Used in Pharmaceutical Industry:
2-Fluoro-6-methoxyphenylboronic acid is used as a reactant for the preparation of functionally selective allosteric modulators of GABAA receptors. These modulators play a crucial role in the treatment of various neurological and psychiatric disorders by targeting specific sites on the GABAA receptor, thus modulating its activity.
Used in Chemical Synthesis:
2-Fluoro-6-methoxyphenylboronic acid is used as a reactant in the Suzuki cross-coupling reaction, a widely employed method for the formation of carbon-carbon bonds. This reaction is essential in the synthesis of complex organic molecules, including those with potential applications in the pharmaceutical, agrochemical, and materials science industries.
Used in Cancer Research:
2-Fluoro-6-methoxyphenylboronic acid is used as a reactant in the preparation of inhibitors of the checkpoint kinase Wee1. Wee1 is a protein kinase involved in the regulation of the cell cycle, and its inhibition has been shown to have potential therapeutic benefits in the treatment of cancer.
Check Digit Verification of cas no
The CAS Registry Mumber 78495-63-3 includes 8 digits separated into 3 groups by hyphens. The first part of the number,starting from the left, has 5 digits, 7,8,4,9 and 5 respectively; the second part has 2 digits, 6 and 3 respectively.
Calculate Digit Verification of CAS Registry Number 78495-63:
(7*7)+(6*8)+(5*4)+(4*9)+(3*5)+(2*6)+(1*3)=183
183 % 10 = 3
So 78495-63-3 is a valid CAS Registry Number.
InChI:InChI=1/C7H8BFO3/c1-12-6-4-2-3-5(9)7(6)8(10)11/h2-4,10-11H,1H3
78495-63-3Relevant articles and documents
IMPROVED SYNTHESIS OF KRAS G12C INHIBITOR COMPOUND
-
Paragraph 0158, (2021/05/21)
The present disclosure relates to an improved, efficient, scalable process to prepare intermediate compounds, such as 2,2',2"-(1,3,5,2,4,6-trioxatriborinane-2,4,6-triyl)tris(3-fluorophenol), useful for the synthesis of compounds, such as Compound 9, for the treatment of KRAS G12C mutated cancers.
COMBINATION THERAPY INCLUDING A KRASG12C INHIBITOR AND ONE OR MORE ADDITIONAL PHARMACEUTICALLY ACTIVE AGENTS FOR THE TREATMENT OF CANCERS
-
Page/Page column 82; 96, (2020/06/10)
The present invention provides combination therapy that includes an KRASG12C inhibitor, such as (see Formula), or a pharmaceutically acceptable salt thereof, and one or more additional pharmaceutically active agents, particularly for the treatment of cancers. The invention also relates to pharmaceutical compositions that contain an KRASG12C inhibitor and one or more additional pharmaceutically active agents for the treatment of cancers.
